SOLAR-PROMOTION-GMBH
The deployment of renewable sources of energy is picking up speed around the world. The impressive results of several market surveys recently presented at The smarter E Europe 2024 prove this. Photovoltaics (PV) and storage systems in particular are experiencing dynamic growth, and the trend goes towards the combination of the two technologies. The number of large-scale PV power plants is growing rapidly, as is the number of residential, commercial and industrial PV installations combined with storage systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711733322/en/
The Global Market Outlook for Solar Power 2024-2028 highlights the dynamic growth of photovoltaics. (Graphic: Business Wire)
SolarPower Europe’s Global Market Outlook for Solar Power 2024–2028 reports a global PV growth of 87 percent in 2023 compared to the previous year. 447 gigawatts (GW) of capacity were installed, which brings the total global capacity to 1.6 terawatts (TW). To put this into perspective, only 239 GW were installed in 2022. According to the study, we are likely to exceed 2 TW of total capacity in the course of this year, after the 1 TW mark was only surmounted in 2022. Achieving the global goal of tripling renewables by 2030 will require financing, digitalizing and flexibilizing energy systems. 1 TW of PV capacity could be installed each year from 2028.
Besides, more and more countries are becoming ‘gigawatt countries’: from 31 in 2023, their number is likely to go up to 37 in 2024. In total, 576 gigawatts of renewable capacity were added last year. While PV makes up by far the largest share at 78 percent, wind power accounts for 20 percent with 117 gigawatts of total capacity. Walburga Hemetsberger, CEO of SolarPower Europe, comments: “The world has truly entered its solar age. How far solar can go will be determined by equitable global access to financing, and the political will to deliver flexible energy systems fit for the renewable reality.”
European storage market is developing dynamically
According to the European Market Outlook for Energy Storage 2024–2028 (also published by SolarPower Europe), 2023 was the year in which Europe saw high electricity prices and the desire to become independent. As a consequence, battery storage capacities skyrocketed. 17.2 gigawatt hours (GWh), that is 94 percent more than last year, were added. This development was mainly driven by the residential sector, where 12 GWh of new capacity were installed. But the commercial and industrial battery sector and on-grid batteries for large-scale energy storage also showed promising developments, adding 1.6 GWh and 3.6 GWh, respectively.
Germany: Record growth of PV
Germany is one of the four leading countries when it comes to solar energy use. The German Solar Association’s (BSW-Solar) study The German PV and Battery Storage Market underlined this with impressive figures: In 2023, added PV capacity grew by 97 percent – the highest registered growth rate in Germany ever recorded. The trend of combining PV systems with battery storage also continued. In 2019, 46 percent of all residential PV systems were installed together with battery storage systems, last year, it was 77 percent. “This trend is likely to continue as supportive regulations are expected to be introduced in the near future,” states David Wedepohl, Managing Director of International Affairs at BSW-Solar. “When combined with intelligent storage systems, the benefits for the energy system go far beyond self-consumption.”
All market surveys are available for free download via the The smarter E Digital on-demand platform:
The smarter E Europe
“Accelerating Integrated Energy Solutions“ – that’s the motto of The smarter E Europe. Europe’s largest alliance of exhibitions for the energy industry puts the spotlight on cross-industry solutions for a renewable 24/7 energy supply covering electricity, heat and transport. The smarter E Europe unites four exhibitions and will take place from May 7–9, 2025 at Messe München.
For more information, please visit: www.TheSmarterE.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711733322/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom